Notably, the interruption of the SDF-1/CXCR4 signaling axis via CXCR4 antagonists diminishes the tumor cells’ migratory and invasive prowess, underscoring the axis’s centrality in PDAC progression [98]. The gene discussed is CXCL12; the disease is neoplasm.